IRONWOOD PHARMACEUTICALS,INC. (NASDAQ:IRWD) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

ME Staff 8-k
-
0

IRONWOOD PHARMACEUTICALS,INC. (NASDAQ:IRWD) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

(b)

On April 13, 2017, Christopher T. Walsh, Ph.D. informed Ironwood Pharmaceuticals, Inc. (the “Company”) that he will transition off of the Company’s board of directors, effective as of the date of the Company’s 2017 annual meeting of stockholders (the “Annual Meeting”) to be held on May 31, 2017. As a result, Dr. Walsh’s term of office as a Class III director of the Company will end as of the date of the Annual Meeting.


About IRONWOOD PHARMACEUTICALS, INC. (NASDAQ:IRWD)

Ironwood Pharmaceuticals, Inc. is a biotechnology company. The Company is advancing product opportunities in areas of unmet need, including irritable bowel syndrome with constipation (IBS C), and chronic idiopathic constipation (CIC), hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease (uncontrolled GERD), and vascular and fibrotic diseases. It operates in human therapeutics business segment. Its product, linaclotide, is available to adult men and women suffering from IBS C or CIC in the United States under the trademarked name LINZESS, and is available to adult men and women suffering from IBS C in certain European countries under the trademarked name CONSTELLA. It is also advancing IW-3718, a gastric retentive formulation of a bile acid sequestrant with the potential to provide symptomatic relief in patients with uncontrolled GERD. Its vascular/fibrotic programs include IW-1973 and IW-1701, which targets soluble guanylate cyclase (sGC).

IRONWOOD PHARMACEUTICALS, INC. (NASDAQ:IRWD) Recent Trading Information

IRONWOOD PHARMACEUTICALS, INC. (NASDAQ:IRWD) closed its last trading session down -0.14 at 15.48 with 725,754 shares trading hands.